SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,231.00    7.00 (0.57%)
Bid:
1,229.00
Ask:
1,230.00
Spread: 1.00 (0.081%)
Market Cap: £858.56m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Non-Executive Director Changes

25 Mar 2026 07:00

RNS Number : 9811X
CVS Group plc
25 March 2026
 

For Immediate Release 25 March 2026

CVS Group plc

("CVS", the "Company" or the "Group")

 

Non-Executive Director Changes

 

CVS, the UK listed veterinary group and a leading provider of veterinary services, is pleased to announce the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee.

 

Retirement of Deborah Kemp

Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026.

 

Appointment of Helen Keays

Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM.

 

From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026.

 

Appointment of Jane Bednall

Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights.

 

From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee.

 

Change in Nomination Committee Chair

David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.

 

David Wilton, CVS Chair commented:

 

"On behalf of the board, I am delighted to welcome Helen Keays and Jane Bednall to CVS and I look forward to working with them. Helen and Jane will strengthen the board through their extensive knowledge and experience in developing consumer propositions and in marketing across a range of client facing businesses.

 

"I would also like to record my profound thanks to Deborah Kemp for her support and for the significant contribution she has made to CVS over the past nine years. Deborah joined the Board in January 2018 as Non-Executive Director and has served as Senior Independent Director, Remuneration Committee Chair, Employee Engagement Director and, for a period of six months, Interim Chair. Deborah has played an important governance role in support of the Group's considerable expansion and will be missed."

 

The Company confirms that there is no further information about Helen Keays or Jane Bednall requiring disclosure under paragraphs 6.4.8R (1) to (6) of the FCA UK Listing Rules.

 

ENDS

 

Contacts

CVS Group plc via Camarco

Richard Fairman, Chief Executive Officer

Scott Morrison, Group Legal Counsel and Company Secretary

 

Camarco (Financial PR)

Ginny Pulbrook cvsg@camarco.co.uk

Tilly Butcher +44 (0)20 3757 4980

Letaba Rimell

 

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAEFLEMSESD
Date   Source Headline
12th Jun 202611:08 amRNSHolding(s) in Company
12th Jun 202610:06 amRNSHolding(s) in Company
8th Jun 20262:43 pmRNSStandard form for notification of major holdings
8th Jun 20262:41 pmRNSUpdated: Transaction in Own Shares
8th Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTotal Voting Rights
28th May 20267:00 amRNSPDMR Dealing
26th May 20267:02 amRNSChanges to NEDs' Responsibilities
26th May 20267:01 amRNSCommencement of Share Buyback Programme
26th May 20267:00 amRNSRefinancing, Launch of SBB and Acquisition
8th May 20263:55 pmRNSStandard form for notification of major holdings
30th Apr 20267:00 amRNSTotal Voting Rights
21st Apr 202612:46 pmRNSNon-Executive Director Appointment
20th Apr 20264:45 pmRNSStandard form for notification of major holdings
31st Mar 20267:00 amRNSTotal Voting Rights
30th Mar 20267:00 amRNSCEO retirement
25th Mar 20267:00 amRNSNon-Executive Director Changes
24th Mar 20267:13 amRNSResponse to CMA Summary Final Decision Report
27th Feb 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSInterim Results
30th Jan 20267:00 amRNSTotal Voting Rights
29th Jan 20262:02 pmRNSStandard form for notification of major holdings
29th Jan 20268:00 amRNSReadmission - CVS Group Plc
29th Jan 20267:00 amRNSAdmission to Trading on the Main Market of the LSE
28th Jan 20267:08 amRNSResponse to DEFRA consultation
27th Jan 20262:31 pmRNSStandard form for notification of major holdings
23rd Jan 202612:19 pmRNSPublication of Prospectus and Trading Update
23rd Jan 20267:00 amRNSProgramme completion and transaction in own shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20269:51 amRNSStandard form for notification of major holdings
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20264:24 pmRNSStandard form for notification of major holdings
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSBlock Listing Interim Review
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20264:31 pmRNSStandard form for notification of major holdings
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20269:34 amRNSDirector/PDMR Shareholding
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.